Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02002130 · ClinicalTrials.gov registry record · Phase 1
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT02002130 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 101 participants.
The verdict
NCT02002130, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
Type I Diabetes is an auto immune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Therefore, children affected by this condition present with high blood sugars. This condition affects 1:400/500 persons worldwide.Type I Diabetes, previously known as Juvenile Diabetes,usually strikes in childhood, adolescence, or young adulthood, but lasts for a lifetime. To date, there has been no treatments that can arrest, or reverse the ongoing beta cell destruction. We hypothesize that GABA, a naturally occurring substance, has the potential to reduce the inflammation and protect the pancreatic beta cells from autoimmune destruction. GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent onset, Type I Diabetes.
Interventions
- DRUG Placebo GABA and Placebo GAD-alum
- DRUG GABA and Placebo GAD-alum
- DRUG Active Oral GABA and Active GAD-alum injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-01 |
| Est. Completion | 2022-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02002130
The ClinicalTrials.gov registry entry for NCT02002130 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo GABA and Placebo GAD-alum is the first listed.
NCT02002130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02002130 about?
NCT02002130 is a clinical study titled "The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes". Type I Diabetes is an auto immune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. Therefore, children affected by this condition present with high blood sugars. This condition affects 1:400/500 persons worldwide.Type I Diabetes, previo...
What is the current status of trial NCT02002130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2015-01. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT02002130?
The interventions under investigation include: Placebo GABA and Placebo GAD-alum (DRUG), GABA and Placebo GAD-alum (DRUG), Active Oral GABA and Active GAD-alum injection (DRUG).
Who is sponsoring clinical trial NCT02002130?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.